Spun-out from the University of Cambridge in 2016, we use proprietary protein purification and engineering technology to make recombinant proteins in E.coli. Their proteins are properly folded, free from contaminating related TGF beta family proteins (unfortunately often present in mammalian protein expression systems) and they include full QC data for every batch – mass spec, analytical reverse phase, recovery, SDS-PAGE, bioassay data and endotoxin testing.
|Modality||Biological & Cell|
|Therapautics Area||Multi Therapautics|
|Investment Portfolio||Fund Investment|
|Co-Investors||Cambridge Enterprise, Business Angels Meltwind|